The reverse merger will likely result in massive dilution for current INM holders, with the combined company effectively a Mentari entity at a $125M valuation. Traders should monitor the S-4 for the exchange ratio and the special meeting date. The stock may trade down as the dilutive structure becomes clear, though near-term volatility could arise from the reverse split and PIPE speculation.
Drugs in focus
INM drug pipeline →MT-001
● Neutral Named in this 8-K- Impact
- Phase
- Preclinical (IND-enabling)
- Time to market
- Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Next catalyst
- None dated
What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $1.57entry
- T+1 · 4mo ago −0.64%α −0.99% · $1.56
- T+5 · 4mo ago −3.18%α −2.40% · $1.52
- T+20 · 3mo ago −10.19%α −13.38% · $1.41
- T+60 · 6w ago −15.29%α −19.28% · $1.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal sequencing, tax treatment, and the impact of pre-closing financing on the exchange ratio. The company also filed an S-4 registration statement for the all-stock reverse merger, expected to close in Q4 2026. The transaction effectively transforms InMed into a migraine-focused biotech (Mentari) with a $125M enterprise value for Mentari, but InMed's current shareholders face massive dilution and a reverse stock split to maintain Nasdaq listing.
Key Financial Metrics
Key Facts
- InMed (INM, $5M market cap) entered into Amendment No. 1 to merge with private biotech Mentari Therapeutics in an all-stock reverse merger.
- Mentari's equity value is set at $125,000,000, implying extreme dilution for current INM shareholders relative to the $5M market cap.
- The amendment introduces a 'Company PIPE Amendment' to allow additional pre-closing financing, which will further dilute the exchange ratio for INM holders.
- A Nasdaq Reverse Split is planned before closing to maintain listing compliance.
- InMed will redomesticate from British Columbia to Nevada and rename to 'Mentari Therapeutics, Inc.' at closing.
- The S-4 registration statement was filed July 2, 2026, but has not yet been declared effective.
- Closing expected in Q4 2026, subject to shareholder approvals for both companies and SEC effectiveness.
Financial Impact
Mentari's equity value is $125M vs. InMed's current market cap of $5M. Existing INM shareholders will retain a minority stake after the reverse merger, with additional dilution possible from the PIPE amendment.
Risk Factors
- Merger may not close if shareholder approvals or SEC effectiveness are not obtained.
- Extreme dilution of INM common shares; current shareholders will own a tiny fraction of the combined company.
- Nasdaq delisting risk if reverse split is not approved or executed in time.
- Mentari's pipeline is preclinical/early clinical, no approved products or revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-077127 |
| Document: ea029728401ex2-2.htm | 0001213900-26-077127 |
| Document: ea029728401ex99-1.htm | 0001213900-26-077127 |
| Document: 0001213900-26-077127-index-headers.html | 0001213900-26-077127 |
| Document: 0001213900-26-077127-index.html | 0001213900-26-077127 |
| Document: 0001213900-26-077127.txt | 0001213900-26-077127 |
Track record
22 reports on INM
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers